object
mani
envelop
virus
carri
carbohydratecontain
protein
surfac
glycoprotein
key
infect
process
mediat
receptor
bind
membran
fusion
virion
host
cell
therefor
attract
therapeut
target
develop
novel
antivir
therapi
recent
carbohydratebind
agent
cba
shown
possess
antivir
activ
toward
coronavirus
current
studi
elucid
inhibitori
mode
action
cba
method
differ
strain
two
coronavirus
mous
hepat
viru
felin
infecti
periton
viru
expos
cba
plant
lectin
galanthu
nivali
agglutinin
hippeastrum
hybrid
agglutinin
urtica
dioica
agglutinin
uda
nonpeptid
mannosebind
antibiot
pradimicin
result
indic
cba
target
two
glycosyl
envelop
glycoprotein
spike
membran
protein
mous
hepat
viru
felin
infecti
periton
viru
furthermor
cba
inhibit
viruscel
attach
rather
affect
viru
entri
postbind
stage
sensit
coronavirus
toward
cba
shown
depend
process
nlink
carbohydr
inhibit
mannosidas
host
cell
render
progeni
virus
sensit
mannosebind
agent
even
nacetylglucosaminebind
uda
addit
inhibit
coronavirus
shown
depend
celltyp
use
grow
viru
stock
togeth
result
show
cba
exhibit
promis
capabl
inhibit
coronaviru
infect
develop
intervent
strategi
coronaviru
infect
boost
sever
acut
respiratori
syndrom
sar
coronaviru
epidem
success
record
demand
antivir
chemotherapeut
safe
activ
low
concentr
perpetu
search
new
compound
use
interferon
human
monoclon
antibodi
research
case
reemerg
sar
coronaviru
coronaviru
entri
includ
fusion
proteas
viral
rna
alreadi
envisag
antivir
target
heavili
glycosyl
coronaviru
envelop
constitut
appeal
target
therapeut
intervent
sugar
content
glycoprotein
critic
effect
replic
viru
viral
protein
glycosyl
play
import
role
cours
viru
infect
replic
viru
host
interact
compound
specif
bind
alter
carbohydr
structur
exterior
glycoprotein
recent
evalu
properti
antivir
agent
demonstr
varieti
carbohydratebind
agent
cba
attach
nglycosyl
molecul
possess
antivir
activ
moreov
seem
genet
barrier
evad
cba
inhibit
alter
nglycosyl
pattern
viral
envelop
glycoprotein
high
henc
resist
mani
cba
easili
acquir
interest
group
cba
plant
lectin
galanthu
nivali
agglutinin
gna
hippeastrum
hybrid
agglutinin
hha
tetramer
andor
mannosebind
protein
previous
found
activ
toward
human
simian
felin
retrovirus
cytomegaloviru
member
nidoviral
order
urtica
dioica
agglutinin
uda
nacetylglucosamin
glcnac
bind
lectin
also
display
pronounc
antivir
properti
deriv
sting
nettl
root
among
smallest
monomer
plant
lectin
known
mannosebind
lectin
deriv
prokaryot
origin
cyanovirin
n
cvn
pradimicin
prma
current
investig
retro
sarscoronaviru
inhibit
properti
prma
actinomycet
actinomadura
hibisca
deriv
dmannosebind
agent
describ
lectinmim
antibiot
shown
activ
fungi
yeast
sever
virus
nidoviral
order
strikingli
prma
demonstr
antivir
activ
serotyp
serotyp
ii
felin
coronavirus
fcov
exact
prma
tropism
current
known
suggest
mannos
configur
nglycan
import
recognit
prma
coronavirus
envelop
plusstrand
rna
virus
invari
contain
least
four
structur
protein
membran
envelop
e
spike
nucleocapsid
n
protein
n
protein
wrap
genom
rna
nucleocapsid
expos
outsid
viru
particl
e
protein
former
two
glycosyl
anchor
envelop
protein
contain
short
ectodomain
abund
envelop
glycoprotein
usual
contain
one
glycan
tree
heavili
glycosyl
protein
mediat
viru
cell
attach
fusion
form
larg
trimer
protrud
virion
surfac
two
differ
coronavirus
use
studi
mode
action
cba
felin
infecti
periton
viru
fipv
strain
caus
progress
system
infect
cat
mous
hepat
viru
mhv
strain
induc
neuropathi
liver
inflamm
mice
interact
cba
differ
viru
envelop
glycoprotein
evalu
furthermor
determin
step
viru
entri
process
affect
cba
final
influenc
glycan
matur
celltyp
specif
glycosyl
inhibit
cba
assess
result
facilit
futur
research
coronaviru
glycosyl
anticoronaviru
therapi
mannosespecif
plant
lectin
gna
hha
nacetylglucosamin
glcnac
specif
uda
deriv
purifi
describ
previous
syncytium
format
experi
cell
infect
mhv
fcwf
cell
fipv
multipl
infect
moi
h
infect
period
cell
wash
three
time
pb
ca
mg
subsequ
cell
incub
presenc
mgl
gna
hha
prma
mgl
uda
uninfect
infect
cell
without
cba
addit
use
control
addit
h
incub
period
co
cell
fix
min
use
methanol
acet
acid
stain
procedur
ident
describ
immunoperoxidas
ipox
assay
fcwf
cell
infect
mhveflm
respect
presenc
variou
concentr
test
compound
fcwf
cell
monolay
infect
moi
virusdrug
mixtur
preincub
co
h
ad
cell
singl
wash
deae
pb
mixtur
remov
h
cell
wash
pb
ca
mg
new
test
compound
dmem
supplement
fb
ad
concentr
h
postinfect
pi
cultur
medium
remov
cell
lyse
use
appropri
buffer
provid
firefli
luciferas
assay
system
promega
madison
wi
usa
intracellular
luciferas
express
measur
accord
manufactur
instruct
rel
light
unit
rlu
determin
turner
design
luminomet
van
der
meer
et
al
effect
concentr
luciferas
express
inhibit
compar
mocktreat
cell
ec
calcul
ec
concentr
antivir
compound
capabl
reduc
luciferas
express
comparison
mocktreat
cell
antivir
activ
measur
base
reduct
focu
form
unit
infect
presenc
variou
concentr
test
compound
cell
monolay
infect
moi
virusdrug
mixtur
preincub
co
h
ad
cell
singl
wash
deae
pb
mixtur
remov
h
cell
wash
pb
ca
mg
new
test
compound
dmem
supplement
fb
ad
h
pi
cell
fix
min
formaldehyd
subsequ
permeabil
ethanol
min
ipox
detect
mhv
gene
mhv
mutant
posit
cell
carri
use
rabbit
polyclon
antibodi
mhv
combin
horseradish
peroxidas
hrp
swineantirabbit
antibodi
dako
glostrup
denmark
ascit
fluid
sampl
cat
succumb
felin
infecti
periton
use
immunodetect
fipv
combin
hrpconjug
goatanticat
antibodi
icn
biomed
inc
aurora
oh
usa
focu
form
unit
count
use
light
microscop
effect
concentr
infect
inhibit
compar
mocktreat
cell
ec
calcul
efficaci
mgl
gna
hha
uda
prma
inhibit
viru
infect
present
differ
stage
infect
process
determin
use
mhveflm
monolay
cell
grown
plate
dmem
contain
fb
iuml
penicillin
mgl
streptomycin
mhveflm
preincub
without
cba
melt
ice
h
cell
also
preincub
melt
ice
min
wash
icecold
deae
pb
inocul
mhveflm
moi
presenc
absenc
antivir
compound
one
hour
postinfect
cell
wash
three
time
icecold
pb
ca
mg
well
ml
prewarm
medium
ad
presenc
absenc
antivir
compound
h
pi
cell
lyse
viru
infect
score
use
luciferas
assay
monolay
cell
fcwf
cell
infect
mhveflm
respect
moi
follow
prior
wash
deae
pb
one
hour
onset
infect
inoculum
remov
cell
wash
three
time
pb
ca
mg
incub
dmem
contain
fb
iuml
penicillin
mgl
streptomycin
mm
dmm
sigma
chemic
co
st
loui
mo
usa
h
pi
medium
harvest
store
viru
deriv
dmmtreat
cell
design
mhveflm
dmm
dmm
control
virus
also
grown
condit
without
addit
dmm
antivir
activ
cba
viru
stock
deriv
dmmand
mocktreat
cell
compar
antivir
assay
perform
obtain
virus
use
infect
host
cell
moi
variou
amount
gna
hha
uda
prma
rang
ngml
mgl
h
pi
cell
lyse
viru
infect
score
use
luciferas
assay
statist
analys
perform
use
student
ttest
coronavirus
contain
two
glycosyl
envelop
protein
may
target
cba
viru
entri
order
discrimin
cba
bind
either
protein
influenc
cba
syncytium
format
studi
express
coronaviru
protein
cell
surfac
sole
respons
cell
cell
fusion
format
multinucl
giant
cell
syncytia
protein
play
role
process
fcwf
cell
infect
mhv
fipv
respect
incub
presenc
absenc
cba
syncytia
abund
infect
cell
without
cba
treatment
wherea
syncytium
format
markedli
reduc
low
level
cba
present
although
syncytia
complet
absent
repres
pictur
shown
figur
uda
hha
potent
syncytiuminhibit
agent
conclud
syncytium
format
significantli
reduc
presenc
cba
like
due
bind
compound
coronaviru
glycoprotein
next
target
envelop
glycoprotein
cba
examin
end
use
mutant
mhv
express
protein
either
olink
sugar
nlink
sugar
sugar
attach
wildtyp
mhv
contain
oglycosyl
site
three
differ
mhv
variant
evalu
sensit
gna
hha
uda
prma
ec
valu
compound
determin
ipox
tabl
order
distinguish
attach
fusion
stage
twostep
entri
process
assay
separ
two
stage
perform
assay
viru
inocul
perform
temperatur
allow
attach
glycoprotein
receptor
fusion
sinc
temperaturesensit
conform
chang
fusion
protein
requir
membran
fusion
arrest
temperatur
fusion
process
start
incub
temperatur
cell
viru
inocul
subsequ
incub
step
presenc
antivir
compound
number
mhveflm
infect
cell
express
rlu
significantli
reduc
figur
presenc
cba
fusion
attach
stage
reduc
infect
uda
prma
use
presenc
hha
uda
prma
bind
stage
inhibit
surprisingli
enhanc
mhveflm
infect
effect
pronounc
uda
similar
procedur
perform
gna
led
case
slight
enhanc
infect
shown
summar
order
inhibit
viru
infect
mannosebind
plant
lectin
gna
hha
must
present
entir
infect
process
uda
prma
primarili
inhibit
postreceptorbind
stage
nlink
glycan
attach
viral
protein
undergo
extens
process
cellular
enzym
matur
stage
nlink
glycan
like
influenc
inhibitori
capac
cba
studi
detail
virus
grown
cell
treat
dmm
sinc
dmm
inhibit
mannosidas
activ
golgi
complex
addit
host
cell
result
progeni
virion
carri
envelop
protein
contain
highmannosetyp
glycan
influenc
highmannosecontain
nglycan
viral
glycoprotein
evalu
use
mhveflm
deriv
host
cell
treat
dmm
design
mhveflm
dmm
dmm
mhveflm
dmm
show
case
much
higher
sensit
cba
inhibit
compar
viru
deriv
nondmmtreat
cell
figur
previou
studi
limit
prma
antivir
activ
toward
detect
mm
interestingli
dmm
clearli
sensit
prma
moreov
glcnacbind
lectin
uda
show
higher
inhibitori
potenc
figur
result
indic
host
cell
significantli
contribut
sensit
virus
cba
addit
note
prma
inhibit
hela
lesser
extent
mhveflm
hela
indic
prma
antivir
activ
affect
host
cell
use
grow
viru
stock
also
viru
product
coronaviru
infect
protein
undergo
seri
conform
chang
follow
attach
viral
receptor
molecul
interact
eventu
mediat
fusion
viral
envelop
host
cell
membran
cba
like
interfer
viru
entri
process
attach
nglycan
protein
although
exact
mode
action
cba
clear
cba
thought
inhibit
infect
via
bind
result
steric
hindranc
detriment
conform
chang
sar
coronaviru
cba
propos
exhibit
dual
mode
action
inhibit
viru
fusion
exocytosi
viral
egress
cell
studi
demonstr
cba
interfer
coronaviru
entri
process
target
nglycosyl
envelop
protein
furthermor
antivir
efficaci
cba
significantli
affect
matur
state
nglycan
envelop
glycoprotein
follow
coronavir
infect
fcwf
cell
fipv
cell
mhv
syncytia
appear
show
gna
hha
uda
prma
markedli
diminish
gener
multinucl
giant
cell
effect
reminisc
inhibit
syncytium
format
cba
observ
cocultur
cell
syncytium
format
upon
coronaviru
infect
graph
first
bar
repres
rlu
product
detect
absenc
cba
incub
phase
normal
note
differ
yaxi
second
bar
indic
rlu
product
presenc
cba
incub
period
third
bar
repres
rlu
product
cba
present
absent
incub
period
last
fourth
bar
show
rlu
product
cba
present
period
incub
period
bar
repres
averag
valu
three
separ
test
error
bar
repres
standard
deviat
normal
experi
sole
induc
protein
indic
protein
direct
target
cba
similarli
syncytiuminduc
shown
select
target
gna
abund
protein
coronaviru
envelop
viru
membran
protein
protein
nglycosyl
coronavirus
includ
infecti
bronchiti
viru
porcin
transmiss
gastroenter
viru
fipv
mhv
studi
influenc
protein
glycosyl
antivir
effect
cba
use
mhv
recombin
recombin
contain
either
n
olink
sugar
sugar
mhv
ectodomain
higher
antivir
activ
compound
detect
virus
contain
protein
nglycosyl
thu
besid
protein
protein
may
also
target
cba
cba
inhibitori
activ
hiv
mainli
result
intervent
cba
viral
fusion
process
rather
attach
hiv
receptor
similar
result
obtain
mhv
viru
attach
inhibit
cba
test
prma
uda
abl
effici
block
viru
entri
ad
postbind
step
inhibitori
activ
hha
gna
howev
becam
appar
agent
present
entir
entri
process
result
may
explain
differ
size
cba
hha
gna
kda
size
prma
uda
much
smaller
kda
respect
specul
larg
cba
must
bind
protein
prior
interact
protein
receptor
strikingli
enhanc
viru
infect
notic
cba
present
attach
phase
surpris
result
might
explain
tether
effect
cba
might
facilit
viru
cell
attach
subsequ
product
infect
inde
cba
evalu
studi
abl
bind
multipl
carbohydr
moieti
role
host
cell
determin
sensit
cba
underscor
observ
alter
sensit
genet
ident
virus
propag
differ
cell
line
sinc
glycan
viru
envelop
protein
synthes
host
cell
glycosyl
machineri
result
indic
cellspecif
glycosyl
may
influenc
abil
cba
case
prma
inhibit
viru
infect
influenc
host
cellspecif
glycosyl
also
demonstr
virus
grown
natur
host
cell
glycan
matur
interf
dmm
addit
dmm
lead
inhibit
golgi
enzym
mannosidas
ii
remov
mannos
residu
viral
glycoprotein
consequ
viral
glycoprotein
contain
immatur
nglycan
high
mannos
type
result
much
higher
sensit
virus
cba
test
appar
mannos
content
nglycan
tree
determin
cba
efficaci
note
also
antivir
activ
uda
increas
toward
virus
carri
high
mannos
glycan
first
glanc
might
suggest
uda
possess
glcnac
mannos
tropism
altern
uda
shown
bind
effici
glcnac
presenc
high
amount
mannos
residu
detail
insight
mode
action
cba
imper
develop
antivir
therapeut
approach
use
agent
use
cba
microbicid
prevent
hiv
infect
vivo
alreadi
propos
coronavirus
induc
diseas
acut
onset
exploit
differ
infect
rout
extern
topic
applic
agent
order
prevent
coronaviru
infect
less
appropri
system
applic
cba
seem
requir
order
cba
function
anticoronavir
agent
next
goal
therefor
establish
safe
system
applic
form
togeth
optim
dosag
regimen
imped
coronaviru
infect
studi
fund
depart
infecti
diseas
immunolog
faculti
veterinari
medicin
utrecht
netherland
